TradingNote
Gurus
Top InvestorsCongress TradesInsider Trades

Top Investors

Warren BuffettCathie WoodLi LuRay DalioBill AckmanView all Top Investors
Archive
Industry
AI & ComputeSoftware & DigitalHealthcare InnovationFinancial InfrastructureEnergy & GridIndustrial AutomationConsumer & CommerceReal Estate & AssetsMaterials & ManufacturingListed Vehicles

AI & Compute

Semiconductors & AcceleratorsCloud & AI PlatformsData Center & NetworkingView all AI & Compute
ResearchApp

ENZB

Enzo Biochem, Inc.

Investor Moves

NameValueActionChangePriceCurrent Price
Ken GriffinCitadel Advisors
$-78.0K
ExitQ2 2025
$78k
--
$0.6989
Jim SimonsRenaissance Technologies
$-770.4K
ExitQ2 2025
$770k
--
$0.6989
Ken GriffinCitadel Advisors
$32.1K
AddQ1 2025
$32k
--
$0.6989
Jim SimonsRenaissance Technologies
$-920.7K
TrimQ1 2025
$921k
--
$0.6989
Ken GriffinCitadel Advisors
$13.5K
AddQ4 2024
$14k
--
$0.6989
Jim SimonsRenaissance Technologies
$-1.1M
TrimQ4 2024
$1M
--
$0.6989
Trade ENZB

About Enzo Biochem, Inc.

Enzo Biochem, Inc. operates as an integrated entity encompassing diagnostics, clinical laboratory services, and life sciences. The company is dedicated to developing, manufacturing, and commercializing diagnostic and research products, fundamentally rooted in genetic engineering, biotechnology, and molecular biology. Its operations are organized into three primary segments: Life Sciences Products, Clinical Laboratory Services, and Therapeutics. The Life Sciences Products division focuses on creating, producing, and distributing essential products and tools for clients engaged in clinical research, pharmaceutical development, and broader bioscience investigations. Its extensive portfolio comprises proteins, antibodies, peptides, small molecules, labeling probes, dyes, and various kits. These offerings empower life science researchers in areas such as target identification and validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis. This segment also serves scientific experts researching a wide array of health issues, including cancer, cardiovascular disorders, neurological diseases, diabetes and obesity, endocrine imbalances, infectious and autoimmune conditions, hepatotoxicity, and renal injury. Through its Clinical Laboratory Services segment, Enzo Biochem provides a spectrum of molecular and other clinical laboratory tests and procedures. These are utilized in routine patient care by medical professionals to aid in establishing or corroborating diagnoses, monitoring treatment efficacy or medication levels, and uncovering previously undiagnosed conditions. This segment operates a full-scale clinical laboratory in Farmingdale, New York, supported by a network of 30 patient service centers throughout New York and New Jersey. Furthermore, it manages specialized "STAT" or rapid response laboratories in New York City and Connecticut, along with a complete phlebotomy center and an internal logistics department. The Therapeutics segment is committed to devising innovative solutions for gastrointestinal, infectious, ophthalmic, and metabolic diseases. Enzo Biochem promotes its products and services globally through a dedicated direct sales force and an established network of distributors. The company was founded in 1976 and maintains its corporate headquarters in New York, New York.

CEO
Kara Cannon
IPO Date
Jun 12, 1980

Market Data

OpenThe first traded price for the current trading session.
$0.695
HighThe highest traded price in the current trading session.
$0.6992
LowThe lowest traded price in the current trading session.
$0.695
VolumeTotal shares traded during the current trading session.
149.7K
Avg VolumeAverage number of shares traded per session, as reported by FMP.
384.3K
52W HighThe highest traded price over the past 52 weeks.
$1.19
52W LowThe lowest traded price over the past 52 weeks.
$0.252

Valuation

Market CapCompany equity value based on share price multiplied by shares outstanding.
$36.6M
Enterprise ValueMarket cap plus debt and other claims, less cash and equivalents.
$2.9M
Dividend YieldAnnualized dividend yield relative to the current share price.
40.0%

Financials

Free Cash FlowOperating cash flow minus capital expenditures from the latest annual cash flow statement.
-$26.8M
RevenueTotal sales from the latest annual income statement.
$31.9M
Net IncomeProfit after expenses and taxes from the latest annual income statement.
-$26.1M
CashCash and equivalents, or cash plus short-term investments, from the latest balance sheet.
$52.4M
DebtTotal debt from the latest balance sheet.
$3.5M

Events

EarningsMar 16

Top Market Industries

AI & Compute
  • Semiconductors & Accelerators
  • Cloud & AI Platforms
  • Data Center & Networking
Software & Digital
  • Enterprise Software
  • Cybersecurity
  • DevTools & Observability
  • Consumer Internet & Marketplaces
  • Digital Advertising & Media
Healthcare
  • GLP-1 & Metabolic Health
  • Biotech & Oncology
  • Medical Devices & Diagnostics
  • Healthcare Services
  • Pharmaceuticals
Financial Infrastructure
  • Banks & Capital Markets
  • Asset Management & Exchanges
  • Insurance
  • Payments & Fintech
  • Digital Assets
Energy & Grid
  • Oil, Gas & Fuels
  • Nuclear & Grid Power
  • Renewables & Storage
  • Utilities
  • Energy Services
Industrial Automation & Defense
  • Aerospace & Defense
  • Robotics & Automation
  • Machinery & Equipment
  • Logistics & Transportation
  • Construction & Infrastructure
Consumer & Commerce
  • Retail & E-commerce
  • Restaurants & Food Service
  • Consumer Brands
  • Autos & Mobility
  • Travel & Leisure
Real Estate & Physical Assets
  • REITs
  • Real Estate Services
  • Housing & Building Products

AI & Compute

  • Semiconductors & Accelerators
  • Cloud & AI Platforms
  • Data Center & Networking

Software & Digital

  • Enterprise Software
  • Cybersecurity
  • DevTools & Observability
  • Consumer Internet & Marketplaces
  • Digital Advertising & Media

Healthcare

  • GLP-1 & Metabolic Health
  • Biotech & Oncology
  • Medical Devices & Diagnostics
  • Healthcare Services
  • Pharmaceuticals

Financial Infrastructure

  • Banks & Capital Markets
  • Asset Management & Exchanges
  • Insurance
  • Payments & Fintech
  • Digital Assets

Energy & Grid

  • Oil, Gas & Fuels
  • Nuclear & Grid Power
  • Renewables & Storage
  • Utilities
  • Energy Services

Industrial Automation & Defense

  • Aerospace & Defense
  • Robotics & Automation
  • Machinery & Equipment
  • Logistics & Transportation
  • Construction & Infrastructure

Consumer & Commerce

  • Retail & E-commerce
  • Restaurants & Food Service
  • Consumer Brands
  • Autos & Mobility
  • Travel & Leisure

Real Estate & Physical Assets

  • REITs
  • Real Estate Services
  • Housing & Building Products
Trending Industries
  • AI & Compute Infrastructure
  • Software & Digital Platforms
  • Healthcare Innovation
  • Financial Infrastructure
  • Energy & Grid
  • Industrial Automation & Defense
  • Consumer & Commerce
  • Real Estate & Physical Assets
Top Investors
  • Warren Buffett
  • Cathie Wood
  • Li Lu
  • Ray Dalio
  • Bill Ackman
  • Duan Yongping
  • Michael Burry
  • Ken Griffin
Trending Stocks
  • NEE
  • NVDA
  • LLY
  • MSFT
  • AAPL
  • META
  • AMD
  • AMZN
Browse
  • App
  • Archive
  • Industries
  • Categories
  • Investors
  • Methodology
  • Watchlist

Trending Industries

  • AI & Compute Infrastructure
  • Software & Digital Platforms
  • Healthcare Innovation
  • Financial Infrastructure
  • Energy & Grid
  • Industrial Automation & Defense
  • Consumer & Commerce
  • Real Estate & Physical Assets

Top Investors

  • Warren Buffett
  • Cathie Wood
  • Li Lu
  • Ray Dalio
  • Bill Ackman
  • Duan Yongping
  • Michael Burry
  • Ken Griffin

Trending Stocks

  • NEE
  • NVDA
  • LLY
  • MSFT
  • AAPL
  • META
  • AMD
  • AMZN

Browse

  • App
  • Archive
  • Industries
  • Categories
  • Investors
  • Methodology
  • Watchlist
© 2026 TradingNote
AppArchiveIndustriesCategoriesInvestorsMethodologyWatchlistPrivacyTerms